On August 4, 2022, Wu, Liang; Deng, Yijun published a patent.Recommanded Product: 882518-89-0 The title of the patent was Targeting chimeric compound, pharmaceutical composition, preparation method and use. And the patent contained the following:
A targeting chimeric compound, a pharmaceutical composition comprising same, a preparation method therefor and use thereof. The targeting chimeric compound is as represented by general formula I [wherein X = CH or N; A = CH=CH, N=N, S, O, or NH; L1 = a bond; L2 = a bond or CO; R1 = OH, alkylsulfonyl, B(OH)2, CO2H, etc.; R2 = independently OH, alkylsulfonyl, CO2H, etc.; R3 and R4 = independently H, alkyl, alkoxy, haloalkyl, etc.; m = 0-5]. Compared with fulvestrant in the prior art, the targeting chimeric compound has comparable or even better proliferative inhibitory activity on estrogen receptor α in mutant drug-resistant cells, and thus is expected to show a comparable or even better therapeutic effect on therapy. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Recommanded Product: 882518-89-0
The Article related to targeting chimeric pharmaceutical composition preparation estrogen receptor inhibitor, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Recommanded Product: 882518-89-0
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics